Press Releases

NEW YORK --(BUSINESS WIRE)--Nov. 22, 2021-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate virtually at the following investor conferences: 33 rd Annual Piper

Schrödinger will receive $4.9 million research grant from the Bill & Melinda Gates Foundation to support early-stage drug discovery of non-hormonal contraceptives NEW YORK --(BUSINESS WIRE)--Nov. 18, 2021-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the

NEW YORK --(BUSINESS WIRE)--Nov. 17, 2021-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on November 15, 2021 , the company granted non-statutory stock options to purchase an aggregate

Third Quarter Total Revenue of $29.9 Million , Up 16 Percent Year-Over-Year; Software Revenue of $24.3 Million Recent Collaboration with Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, Highlights Continued Large-Scale Adoption of Platform by Biotechnology Companies Development Candidate

NEW YORK --(BUSINESS WIRE)--Nov. 9, 2021-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference .

NEW YORK --(BUSINESS WIRE)--Nov. 4, 2021-- Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its small-molecule MALT1 inhibitors will be presented during a poster

NEW YORK --(BUSINESS WIRE)--Oct. 29, 2021-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Wednesday, November 10, 2021 , at 4:30 p.m.

Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications First time Schrödinger is applying its computational platform in an orexin agonist setting enabled by Orexia’s structural biology

NEW YORK --(BUSINESS WIRE)--Oct. 18, 2021-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on October 15, 2021 , the company granted non-statutory stock options to purchase an aggregate

Translational research will focus on advancing therapeutic strategies for Schrödinger’s selective WEE1 inhibitors to optimally benefit patients HOUSTON & NEW YORK --(BUSINESS WIRE)--Oct. 7, 2021-- The University of Texas MD Anderson Cancer Center and Schrödinger, Inc.
Displaying 1 - 10 of 36
Back To Top